NEW YORK (GenomeWeb) – MDxHealth reported today that its third quarter revenues rose 122 percent, driven by a sharp increase in the number of payors issuing positive coverage decisions for its ConfirmMDx and SelectMDx prostate cancer tests.

For the three months ended Sept. 30, the Belgian molecular diagnostics company said revenues rose to $9.1 million from $4.1 million in Q3 2015.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.